SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAVAZZINI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.718
EU - Europa 2.275
AS - Asia 1.588
OC - Oceania 7
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 2
Totale 12.601
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.713
CN - Cina 1.039
DE - Germania 539
UA - Ucraina 511
TR - Turchia 467
IT - Italia 382
GB - Regno Unito 263
SE - Svezia 202
FI - Finlandia 120
FR - Francia 77
PL - Polonia 62
RU - Federazione Russa 56
BE - Belgio 31
VN - Vietnam 22
IN - India 17
HK - Hong Kong 15
AU - Australia 6
JP - Giappone 6
CA - Canada 5
EU - Europa 5
IE - Irlanda 5
IR - Iran 5
NL - Olanda 5
BR - Brasile 4
IL - Israele 4
KR - Corea 3
AT - Austria 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
ES - Italia 2
KZ - Kazakistan 2
PT - Portogallo 2
RO - Romania 2
SG - Singapore 2
BD - Bangladesh 1
BO - Bolivia 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
LT - Lituania 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RS - Serbia 1
RW - Ruanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 12.601
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.238
Fairfield 1.181
Houston 814
Chandler 648
Jacksonville 625
Ashburn 539
Ann Arbor 487
Seattle 451
Wilmington 424
Cambridge 378
Beijing 342
Izmir 226
Nanjing 199
Princeton 170
Ferrara 152
New York 122
San Diego 112
Boardman 106
Addison 90
Shanghai 83
Milan 69
Shenyang 67
Nanchang 63
Warsaw 60
Bremen 45
Hebei 45
Falls Church 33
Redwood City 32
Brussels 31
Changsha 30
Jinan 29
Tianjin 29
Jiaxing 27
London 27
Mountain View 23
Dong Ket 22
Dearborn 21
Zhengzhou 21
Los Angeles 19
Norwalk 19
Des Moines 17
San Mateo 15
Hong Kong 14
Kunming 14
Ningbo 14
Orange 13
San Jose 13
Auburn Hills 12
Guangzhou 12
Hefei 12
Leawood 12
Tappahannock 11
Indiana 10
Washington 10
Chicago 8
Fuzhou 8
Taizhou 8
Hangzhou 7
San Francisco 7
Augusta 6
Helsinki 6
Kilburn 6
Philadelphia 6
Redmond 6
Siena 6
Dublin 5
Bologna 4
Chengdu 4
Haikou 4
Lanzhou 4
Minerbe 4
Monmouth Junction 4
Palermo 4
Rome 4
Torino 4
Acton 3
Ahmedabad 3
Changchun 3
Chiswick 3
Edinburgh 3
Hounslow 3
Illasi 3
Kobe 3
Lagopesole 3
Simi Valley 3
Stockholm 3
Toronto 3
Verona 3
Ardabil 2
Atlanta 2
Berlin 2
Boston 2
Chongqing 2
Civitavecchia 2
Colle Di Val D'elsa 2
Frankfurt am Main 2
Lappeenranta 2
Napoli 2
Newark 2
Nürnberg 2
Totale 9.456
Salva come PNG Salva come JPEG
Nome #
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI 175
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 152
Diagnostic work-up for clinical and prognostic assessment of acute leukaemia 148
Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 131
Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype 130
Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. 125
Acute Human Herpesvirus-6A infection of human mesothelial cells modulates HLA molecules 125
Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in SplenicMarginal Zone Lymphoma 125
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 124
null 124
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy 124
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients 122
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 120
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: Clinical and biological correlations 119
Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype 118
Soluble urokinase-type Plasminogen Activator Receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients 116
CYTOGENETIC ABERRATIONS IN THE CD38 POSITIVE FRACTION OF CD38 NEGATIVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: A MARKER OF AGGRESSIVENESS? 115
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 115
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 113
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 112
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 112
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations 111
Hepatosplenic T-cell lymphoma (HSTCL). 110
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 110
Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. 108
Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis 108
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 107
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 107
Myelofibrosis with Myeloid Metaplasia (MMM)/Idiopathic myelofibrosis/Agnogenic myeloid metaplasia 106
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13) PDGFRB-NDE1 fusion 105
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 105
Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays 105
Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations (J Hematol Oncol. (2016) 9 (88) DOI:10.1186/s13045-016-0320-z) 105
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 105
A novel recurrent translocation t(11;14)(p11;q32) in splenic marginal zone B cell lymphoma 105
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 104
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 103
Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival 103
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 103
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements 102
Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. 102
null 100
HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB 100
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. 99
Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. 98
Intestinal T-cell lymphoma 98
A highly sensitive and specific fluorescence in situ hybridization (FISH) approach for the detection of t(9;11)(p22-23;q23) in acute myeloid leukemia. 97
CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA 97
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 96
“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia” 96
THE EUTOS LONG-TERM SURVIVAL SCORE IS PREDICTIVE FOR RESPONSE AND OUTCOME IN CML PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 96
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients. 95
Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome 95
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) 94
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia 94
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. 93
B-Cell chronic lymphocytic leukemia (B-CLL) with 14q32 translocations: haematological features and clinical outcome. 92
Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21 92
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters 92
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 91
Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance 90
VERY ELDERLY CP-CML PATIENTS TREATED WITH IMATINIB FRONTLINE: HAVE CONCOMITANT THERAPIES AN IMPACT ON OUTCOME AND TOXICITY? 90
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 90
Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. 88
Molecular cytogenetic characterization of marginal zone B-cell lymphoma: correlation with clinicopathologic findings in 14 cases 88
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB 88
null 88
APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS 87
Identifying High-Risk Chronic Lymphocytic Leukemia: A Reappraisal of the Impact of Prognostic and Predictive Factors 87
Chromosome Aberrations by Conventional Karyotyping in Chronic Lymphocytic Leukemia Carrying No Aberration by Fluorescence in Situ Hybridization: Correlation with Prognostic Parameters and Clinical Features 86
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 86
IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB 85
Abnormalities of chromosomes 1p34-36, 4p16, 4q35, 9q11-32 and +7 represent novel recurrent cytogenetic rearrangements in chronic lymphocytic leukemia 85
null 85
Alterazioni cromosomiche in cellule staminali emopoietiche indotte da esposizioni ambientali o professionali. 84
Imatinib In Very Elderly CML Patients: What Can We Achieve? 84
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. 84
Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. 83
CHROMOSOME ABNORMALITIES ADDITIONAL TO THE PHILADELPHIA CHROMOSOME AT THE DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA. PATHOGENETIC AND PROGNOSTIC IMPLICATIONS. 83
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia 83
Essential Thrombocythemia (ET) 83
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 83
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated with Ibrutinib 82
Cytogenetic and molecular cytogenetic characterization of 6 new cases of idiopathic hypereosinophilic syndrome 80
Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. 79
Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party 79
null 78
null 78
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 78
TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA 77
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 77
A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line 77
Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis 77
The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia 74
LONG-TERM OUTCOME TO FIRST-LINE IMATINIB ACCORDING TO 2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA: A GIMEMA CML WP ANALYSIS 73
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 73
Significato dell'analisi citogenetica e citogenetico-molecolare nella diagnosi e nella prognosi delle neoplasie ematologiche. Cytogenetics and molecular cytogenetics in diagnosis and prognosis of haematological malignancies 72
Clonal evolution in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients 72
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study 71
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 68
Totale 9.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.499
Totale 52.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019896 0 0 0 0 0 0 0 0 0 0 292 604
2019/20202.894 438 72 79 420 209 357 277 292 259 299 135 57
2020/20212.170 141 149 91 207 121 200 71 241 41 322 396 190
2021/20221.647 129 188 54 59 84 112 93 97 44 137 163 487
2022/20231.579 180 88 64 182 259 209 74 167 210 7 89 50
2023/2024545 79 91 37 18 38 143 42 54 24 16 3 0
Totale 12.874